Objective: To evaluate the effect of low-dose heparin on duration of peripherally inserted percutaneous central venous catheter (PCVC) patency and catheter occlusion.
Introduction
Neonates treated in neonatal intensive care units (NICUs) usually need prolonged venous access for the administration of medications and total parenteral nutrition (TPN). Peripheral intravenous (PIV) and umbilical catheters are commonly used to provide venous access. However, they have some disadvantages such as limited dwelling time, mechanical and infectious complications and the need for frequent changes of the PIV catheter site. [1] [2] [3] [4] In the 1970s, a new frontier was forged with peripherally inserted percutaneous central venous catheters (PCVCs). Lawson performed the first research with PCVCs in adult oncology patients. 5 In 1973, Shaw first described a novel technique for inserting a PCVC in neonates. 6 The PCVC was defined as a tool placed into a peripheral vein and advanced into the central vein. 7 Although PCVC is the preferred route of venous access in many NICUs, it has some complications such as mechanical problems and infections. 8, 9 The common mechanical complication is catheter occlusion, and it can occur in 15 to 48% of placed PCVCs. 10 Few earlier studies supporting the use of heparin suggest that it decreases the risk of blockage in the PCVC. 11, 12 The main objective of this study was to determine the efficacy of low-dose heparin addition to TPN fluids in preventing PCVC occlusion and thus prolonging catheter patency in sick newborns. Secondary outcomes were to compare the effect of TPN fluids with heparin on the incidence of thrombus, phlebitis, catheter-related sepsis, septicemia, death, intracranial hemorrhage, arrythmia and hematologic disturbances like thrombocytopenia and prolonged activated partial thromboplastin time (aPTT).
Methods
The study was a prospective, randomized, controlled, double-blind clinical trial. It was performed at the NICU of Diyarbakir Children's Hospital, Diyarbakir, Turkey, during a 21-month period between 1 February 2007 and 31 October 2008. It was approved by the regional ethical committee, and informed consent was obtained from parents. All neonates admitted to NICU who had required a PCVC, as determined by the attending neonatologist were included. Neonates with bleeding tendencies, grade 3 to 4 intraventricular hemorrhage, 13 recent suspected or confirmed sepsis (within 48 h of initiation of antibiotic therapy), thrombocytopenia (<100 000 mm À3 ), disseminated intravascular coagulation, arrythmia and congenital malformations were excluded. Uncertain viability (this was based on the discretion of the neonatologist), need for use of heparin (umbilical arterial catheter) and a prolonged aPTT (>74 s for preterm infants and >51 s for term infants) were the other criteria for exclusion. Catheter placement and confirmation of optimal position were performed by the same neonatologist. Two different types of catheters were used (27G Premicath (Vygon, Germany) or 23G Nutriline (Vygon, Germany)). Both catheters were placed by using a sterile technique. Catheter type and place of insertion were determined by the physician's choice. Catheters were stabilized and secured with a transparent medical film dressing (Tegaderm; 3M; St Paul, MN, USA), which was not changed unless it became polluted or slack. Catheters were not to be used for collecting blood sample and transfusion. Correct placement of the PCVC was assured by radiography as a standard procedure. Catheter tip location was defined as 'in the correct position' when the catheter tip floated in the vena cava (superior vena cava or inferior vena cava). Correct location for upper body insertions was accepted as the lower ½ to 1 /3 part of the superior vena cava (T3 to T5 level). The appropriate inferior vena cava tip placement was described as being located between the right atrium and the diaphragm (T8 to T10 level). 7 Randomization was performed after confirmation that the PCVC was in the correct position by the same neonatal nurse. A neonatal nurse randomly selected a card from a black purse containing labeled cards, which were previously arranged as either the heparin group or no-heparin group. The nurse responsible for the randomization did not participate in the trial.
Neonatologist and data collector neonatal nurse were masked to the grouping. In the heparin group, heparin was infused within TPN solutions (for a TPN infusion rate of 1 cc/kg/h) at a rate of 0.5 IU kg À1 h
À1
. The TPN fluids of the no-heparin group did not contain heparin. The two different solutions were used for TPN; one of them was amino acid based (Primene 10%; Eczacibasi-Baxter, Turkey) and the other was lipid based (Intralipid 20%; Fresenius Kabi, Sweden). Unfractioned heparin (Heparin-sodium 5000 IU ml À1 (Nevparin, Mustafa Nevzat, Turkey)) was used for the trial.
Catheter sites were monitored closely, and time and reason for any removal of PCVC were recorded by the neonatal nurse (inspection, catheter care and data collection were performed by the data collector neonatal nurse). The criteria for removal were defined as follows: signs of local or systemic infection, phlebitis, extravasation, blockage, breakage and leakage of catheter, accidental removal, death and if neonate reached close to full enteral feeds.
After removal of PCVC, it was inspected for blockage and infused with normal saline for detection of any clot. Bacterial cultures were obtained from catheters and flushing solutions. In case of suspicion of septicemia, blood culture was obtained from a peripheral vein.
The study was terminated when complications developed (such as platelet count <50 000 mm À3 , aPTT increase above 100 s, evidence of hemorrhage). When the adverse events occurred, the trial was terminated and randomization information was evaluated (defined as 'code break'). Platelet counts and aPTT levels were evaluated before the insertion of the catheter, then in weekly intervals, in case of suspicion of a bleeding tendency and at catheter removal. The length of the catheter outside the skin and the flow rate of TPN fluids were noted. Routine cranial ultrasound was performed in all neonates on days 1, 7 and immediately after catheter removal or in case of suspicion of bleeding. Electrocardiographic evaluation was performed in all neonates before insertion and after removal of PCVC or in case of suspicion of arrythmia.
Duration of catheter was defined as the number of days between insertion and removal. As identified in the study of Kamala et al., 11 catheter occlusion was defined as the inability of infusing fluids through the catheter due to blockage (it was confirmed by flushing 1 ml of normal saline via 5-ml syringe). In the same study, thrombosis was defined as a thrombus along the catheter line detected by inspection after removal of the catheter.
Phlebitis was defined by inspection as swelling, hyperemia and change in skin color associated with an inflamed vein. Catheterrelated sepsis was defined as clinical signs of sepsis associated with a positive peripheral blood culture and positive catheter culture of the same organism. Successful completion of TPN was defined as when full enteral feeding was successfully tolerated.
The SPSS statistical package (SPSS 11.5, Chicago, IL, USA) was used for analysis of trial. Comparison was made using the w 2 test (or Fisher's exact test for variables with expected value <5) for categorical variables, and the Student's t-test for normally distributed continuous variables. Univariate logistic regression was used to identify risk factors. The median duration of catheters with completed TPN of the two groups was evaluated by using a Kaplan-Meier curve and was compared by using the log-rank test. These results were presented graphically for both groups. A value of P<0.05 was considered significant.
Results
During the study period, 612 PCVCs were placed peripherally to the newborn infants in NICU. Three hundred and sixty-six of them were not included in the trial for the following reasons: the Effect of low-dose heparin S Uslu et al presence of exclusion criteria, unavailability of the parents (for informed consent), refusion of trial, randomization error, failed insertion and false positioning of the catheter. A total of 239 patients were randomized successfully. One hundred and eighteen infants received heparin, and 121 infants did not. The study was terminated before completion of therapy in six infants. The reasons for this were as follows: development of thrombocytopenia (two infants from heparin and one from no-heparin group), clinical bleeding tendencies (one infant from heparin and one from noheparin group) and prolonged aPTT>100 s (one infant from the heparin group). Other outcomes of PCVCs were demonstrated in Figure 1 . Clinical and demographic characteristics of infants were similar between the two groups ( Table 1) .
The catheter-related outcomes were compared between two groups in Table 2 . In the heparin group, the duration of catheter patency was longer than the no-heparin group (12.4 ± 4.5 vs 9.7 ± 4.0, P<0.0001), the difference being statistically significant. There was a statistically significant increase in the duration of the catheter patency with completed TPN in the heparin group vs no-heparin group by the analyzed Kaplan-Meier curves and log-rank tests (Figure 2 ).
Successful completion of TPN therapy was significantly more common in the heparin group (P ¼ 0.0001; relative risk (RR): 3.32 (95% confidence interval (CI): 1.92 to 5.73)). The proportion of the infants with catheter occlusion in the heparin group was smaller (P ¼ 0.0001; RR: 3.44 (95% CI: 1.92 to 6.44)). This means that the frequency of catheter occlusion observed in the heparin group was 3.4 times lower than in the no-heparin group. There were no statistically significant differences between the two groups in the incidence of other catheter-related problems (thrombus, phlebitis, catheter-related sepsis, septicemia, death, breakage, leakage, accidental withdrawal, thrombocytopenia, prolonged aPTT>100 s, intracranial hemorrhage, arrythmia).
When we compared the mean value of the length of the catheter outside the skin, TPN infusion rate and catheter duration time among neonates who had occluded or not-occluded catheters, we found that the length of the catheter outside the skin was longer, TPN infusion rate was lower and the catheter duration time was longer in occluded catheters (Table 3) .
Mean value of the length of the occluded catheter outside the skin and TPN infusion rate at the occlusion of PCVC were not statistically significant between heparin and no-heparin groups. But in the heparin group, catheter duration time was significantly longer than the no-heparin group among the infants who had occluded catheters. A comparison of occlusion-related factors between heparin and no-heparin groups for occluded catheters are presented in Table 4 . Effect of low-dose heparin S Uslu et al
Discussion
In this study, we showed that low-dose heparin addition to TPN solutions was effective in prolonging the duration of PCVC patency in neonates without increasing adverse effects. Previous two randomized controlled studies showed that heparin was effective in prolonging the duration of catheter patency, but this was not found to be statistically significant. 11, 12 In studies including newborns and patients in different age groups, heparin was shown to prolong the duration of peripheral catheter patency. [14] [15] [16] [17] We found that average duration of the catheter use was significantly longer in heparin group (12.4±4.5 days vs 9.7±4.0 days). Similar to the results of Kamala et al. 11 and Shah et al., 12 we showed that after completion of therapy, the likelihood of elective catheter removal (completed TPN therapy) was higher (53.5 vs 25.6%, P ¼ 0.001) and the incidence of catheter occlusion was lower in the heparin group (19.5 vs 45.5%, P ¼ 0.001).
In our study, we found that the duration of maintenance of catheter in the correct position was longer in occluded catheters. In Effect of low-dose heparin S Uslu et al other words, as the duration of catheter placement in the vein increases, the risk of occlusion also increases. When we compared the occluded catheter groups with each other, we found that the duration of catheter patency was longer in heparin group than in the no-heparin group. Thus, heparin decreased the risk of occlusion in catheters with high risk of occlusion. This effect of heparin developed independent of the rate of TPN infusion and the length of the catheter outside the skin.
Ruggiero and Aisenstein found fibrin sleeve formation in 11 of 17 (65%) central venous catheters by catheter venograms at the conclusion of the therapy. 18 In another study, Nakamura detected 33% complete and 33% partial occlusion of the catheter tip with electron microscopy. 19 Earlier studies have shown that the duration of the catheter patency correlates with the incidence of intravascular fibrin sleeve formation. [20] [21] [22] Unfortunately, we could not define the fibrin sleeve formation at the catheters in our study. The fibrin sleeve formation might be the cause of catheter occlusion, and heparin might have an effect on this clot formation as some authors suggest. 23 According to the results of our study, we speculate that addition of low-dose heparin to TPN fluids acts on the formation of fibrin sleeves just before thrombus formation leading to the prevention of catheter occlusion. This hypothesis is supported by the assumption that heparin is effective via other occlusion-related factors, which are not detected in this study.
Similar to the findings of other studies, our trial suggested that low dose of heparin was not associated with catheter-related sepsis, septicemia, thrombocytopenia, prolonged aPTT, intracranial hemorrhage, arrythmia and death. 11, 12, 24, 25 The low rate of complications in our study may be related to the use of low-dose heparin as suggested in the literature. Trials with higher number of patients and with different dosages of heparin may show the adverse effects of heparin.
Low-dose continuous infusion of heparin (0.5 IU kg À1 h À1 ) with TPN fluids for PCVC is effective in terms of successful completion of the therapy due to reduced catheter occlusion without increasing adverse effects. Furthermore, this effect of heparin may occur independently via occlusion-related factors that we evaluated in the study. Effect of low-dose heparin S Uslu et al
